B. Metzler seel. Sohn & Co. AG Sells 10,087 Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO)

B. Metzler seel. Sohn & Co. AG lowered its position in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 30.4% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 23,096 shares of the biopharmaceutical company's stock after selling 10,087 shares during the period. B. Metzler seel. Sohn & Co. AG's holdings in Halozyme Therapeutics were worth $1,104,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also added to or reduced their stakes in the company. Norges Bank acquired a new stake in shares of Halozyme Therapeutics during the fourth quarter worth $60,054,000. Arrowstreet Capital Limited Partnership increased its position in Halozyme Therapeutics by 141.3% during the fourth quarter. Arrowstreet Capital Limited Partnership now owns 992,887 shares of the biopharmaceutical company's stock worth $47,470,000 after acquiring an additional 581,475 shares during the period. Raymond James Financial Inc. acquired a new stake in Halozyme Therapeutics in the 4th quarter worth about $21,838,000. Vanguard Group Inc. boosted its holdings in Halozyme Therapeutics by 3.0% in the 4th quarter. Vanguard Group Inc. now owns 13,281,714 shares of the biopharmaceutical company's stock valued at $634,999,000 after purchasing an additional 386,618 shares during the period. Finally, Janney Montgomery Scott LLC grew its position in shares of Halozyme Therapeutics by 698.8% during the 4th quarter. Janney Montgomery Scott LLC now owns 287,731 shares of the biopharmaceutical company's stock worth $13,756,000 after purchasing an additional 251,711 shares in the last quarter. 97.79% of the stock is owned by institutional investors and hedge funds.

Remove Ads

Insider Buying and Selling

In other Halozyme Therapeutics news, SVP Michael J. Labarre sold 10,000 shares of the firm's stock in a transaction that occurred on Tuesday, February 25th. The shares were sold at an average price of $58.05, for a total transaction of $580,500.00. Following the completion of the transaction, the senior vice president now owns 185,453 shares in the company, valued at approximately $10,765,546.65. This trade represents a 5.12 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Jeffrey William Henderson sold 503 shares of the company's stock in a transaction on Tuesday, April 1st. The shares were sold at an average price of $64.05, for a total transaction of $32,217.15. Following the completion of the sale, the director now directly owns 33,108 shares in the company, valued at approximately $2,120,567.40. This represents a 1.50 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 22,200 shares of company stock valued at $1,286,568 over the last ninety days. 2.40% of the stock is owned by company insiders.

Halozyme Therapeutics Trading Up 1.7 %

HALO traded up $1.00 during trading on Tuesday, reaching $60.35. 307,980 shares of the company's stock were exchanged, compared to its average volume of 1,390,979. The firm has a fifty day moving average price of $59.89 and a two-hundred day moving average price of $54.82. The stock has a market capitalization of $7.45 billion, a PE ratio of 17.60, a price-to-earnings-growth ratio of 0.42 and a beta of 1.32. Halozyme Therapeutics, Inc. has a one year low of $37.73 and a one year high of $66.00. The company has a current ratio of 7.80, a quick ratio of 9.15 and a debt-to-equity ratio of 4.14.

Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last posted its quarterly earnings data on Tuesday, February 18th. The biopharmaceutical company reported $1.19 earnings per share for the quarter, beating analysts' consensus estimates of $1.17 by $0.02. The business had revenue of $298.01 million during the quarter, compared to the consensus estimate of $285.74 million. Halozyme Therapeutics had a return on equity of 157.78% and a net margin of 43.74%. As a group, equities research analysts forecast that Halozyme Therapeutics, Inc. will post 4.73 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

HALO has been the subject of several recent research reports. HC Wainwright reiterated a "buy" rating on shares of Halozyme Therapeutics in a research note on Thursday, March 6th. Benchmark reissued a "buy" rating and set a $75.00 target price on shares of Halozyme Therapeutics in a report on Thursday, February 20th. Piper Sandler boosted their price target on Halozyme Therapeutics from $52.00 to $53.00 and gave the company a "neutral" rating in a research note on Friday, January 10th. Finally, Wells Fargo & Company reduced their price objective on shares of Halozyme Therapeutics from $62.00 to $57.00 and set an "equal weight" rating on the stock in a research note on Monday, January 13th. Four investment analysts have rated the stock with a hold rating and six have given a buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $62.78.

Halozyme Therapeutics Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.